Allogene Therapeutics, Inc. (ALLO)
| Previous close | 5.02 |
| Open | 5.02 |
| Bid | 5.08 x 800 |
| Ask | 5.08 x 1200 |
| Day's range | 4.96 - 5.20 |
| 52-week range | 4.91 - 17.49 |
| Volume | |
| Avg. volume | 1,912,671 |
| Market cap | 731.155M |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.12 |
| Earnings date | 02 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.81 |
- GlobeNewswire
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
Initial Data Provide Proof-of-Concept for an anti-CD70 AlloCAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting TherapyALLO-316 Data Also Highlight the Potential of Dagger™ Technology, a Next Generation Allogeneic Platform Designed to Control Immune Rejection of AlloCAR T Cells SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company p
- Zacks
Roche (RHHBY) Polivy Combo Backed by FDA Advisory Committee
Roche (RHHBY) gets majority votes from the FDA's Advisory Committee for Polivy combination for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL).
- Zacks
Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate
Trevena (TRVN) has initiated proof-of-concept study to evaluate TRV045 as a potential treatment for epilepsy and other CNS disorders.
